New technology to tackle treatment-resistant cancers

Free-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies.

Read more

Simple test to help diagnose bowel and pancreatic cancer could save thousands of lives

A simple online calculator could offer family GPs a powerful new tool in tackling two of the most deadly forms of cancer, say researchers.

Academics from The University of Nottingham and ClinRisk Ltd have developed two new QCancer algorithms, which cross-reference symptoms and risk factors of patients to red flag those most likely to have pancreatic and bowel cancer, which could help doctors to diagnose these illnesses more quickly and potentially save thousands of lives every year.

Read more

Scientists develop vaccine that successfully attacks breast cancer in mice

Researchers at Mayo Clinic in Arizona (http://www.mayoclinic.org/arizona/) and the University of Georgia (UGA) have developed a vaccine that dramatically reduces tumors in a mouse model that mimics 90 percent of human breast and pancreatic cancer cases — including those that are resistant to common treatments.

Read more

Mayo Clinic reports new findings on noninvasive test for pancreatic cancer

ROCHESTER, Minn. - Pancreatic cancer has one of the highest mortality rates of any of the major cancers, and of the 43,000-plus Americans diagnosed with the disease each year, more than 94 percent die within five years of diagnosis. One reason for this high number of deaths is a lack of effective screening tools for catching the disease early. Now, in an effort to try to gain the upper hand on this deadly form of cancer, Mayo Clinic researchers believe they have found a new way to test for pancreatic cancer with DNA testing of patients’ stool samples. The research was presented at the 2011 Digestive Disease Week conference, held May 7󈝶 in Chicago.

Read more

New drug is effective against the most common form of skin cancer

Noted TGen-Scottsdale Healthcare oncologist discusses vismodegib study at AACR

ORLANDO, Fla. — April 5, 2011 — A new drug is effective in preventing new basal cell carcinomas in patients with an inherited predisposition to the disease.

Read more

Researchers find possible new treatment strategies for pancreatic cancer

Athens, Ga. – New University of Georgia research has identified a protein that can be modified to improve the effectiveness of one of the most common drugs used to treat pancreatic cancer.

The research, published in the March edition of the journal Cancer Research, found that a cell-surface protein called CNT1, which transports cancer-killing drugs into tumor cells, was reduced in function in two thirds of pancreatic tumors. By improving the function of CNT1, the researchers increased the effectiveness of the cancer-killing drugs in pancreatic tumor cells derived from human patients, said lead-author Raj Govindarajan, assistant professor of pharmaceutical and biomedical sciences in the UGA College of Pharmacy.

Read more

University of Oklahoma scientists discover way to stop pancreatic cancer in early stages

Growth inhibitor to clinical trial to help at-risk patients; leading pancreatic cancer specialists call finding ‘provocative’

Cancer researchers at The Peggy and Charles Stephenson Oklahoma Cancer Center have found a way to stop early stage pancreatic cancer in research models – a result that has far-reaching implications in chemoprevention for high-risk patients.

Read more

Missing molecules hold promise of therapy for pancreatic cancer

Lost microRNAs put brakes on tumors

By determining what goes missing in human cells when the gene that is most commonly mutated in pancreatic cancer gets turned on, Johns Hopkins scientists have discovered a potential strategy for therapy.

Read more

Forces for cancer spread: Genomic instability and evolutionary selection

Pancreatic cancer genomes show remarkable mutation effects

In new research published today, researchers uncover evolution in action in cancer cells. They show the forces of evolution in pancreatic tumours mean that not only is cancer genetically different between different patients, but each new focus of cancer spread within a patient has acquired distinct mutations.

Read more

New investigational compound targets pancreatic cancer cells

World’s first patient treated at Virginia G. Piper Cancer Center at Scottsdale Healthcare

SCOTTSDALE, Ariz. (Sept. 14, 2010) – A new investigational drug designed to penetrate and attack pancreatic cancer cells has been administered to a patient for the first time ever at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

Read more

Next Page »